Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
Сахарный диабет, 2014 Glargine became the first long-acting insulin analogue. Glargine was designed to meet basal insulin requirements throughout the day with a single injection.
Vadim Valer'evich Klimontov +1 more
doaj +1 more source
PLoS ONE, 2021 Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years.
Parag Goyal +24 more
doaj +1 more source
The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]
, 2018 Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group +47 more
core +1 more source
The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn
Journal of Diabetes Science and Technology, 2021 On March 23, 2020, all insulin products were reclassified as biologics instead of drugs under the Biological Price Competition and Innovation (BPCI) Act of 2009.
Mark Matli +5 more
semanticscholar +1 more source
Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment [PDF]
, 2018 An 8-year-old male neutered Persian cat was presented with polyuria, polydipsia, polyphagia and muscle weakness associated with a 7 month history of diabetes mellitus (DM).
Adriana Cunha Muschner +4 more
core +3 more sources
Increasing the production of insulin glargine in Pichia pastoris through medium modification [PDF]
BIO Web of ConferencesInsulin is the primary drug for managing diabetes mellitus, especially for individuals with type 1 diabetes mellitus. Producing insulin glargine, a long-acting insulin analogue, using Pichia pastoris is a notable advancement in biopharmaceutical ...
Hardianto Dudi +7 more
doaj +1 more source
Insulin glargine affects the expression of Igf-1r, Insr, and Igf-1 genes in colon and liver of diabetic rats [PDF]
Iranian Journal of Basic Medical Sciences, 2018 Objective(s): The mitogenic effect of the analogous insulin glargine is currently under debate since several clinical studies have raised the possibility that insulin glargine treatment has a carcinogenic potential in different tissues.
Clara I Juárez-Vázquez +8 more
doaj +1 more source
Clinical Diabetology, 2021 Background. Basal-bolus insulin therapy is the most widely accepted method of glycemic control in non-critically ill patients with T2DM. In this regimen glargine U100 is the most commonly used basal insulin.
Asis Mitra, Saswati Ray, Sushma Jayan
doaj +1 more source
Comparison of insulin detemir and insulin glargine in a Basal-Bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial [PDF]
, 2009 Objective: The primary study objective was to determine whether insulin detemir (detemir) was noninferior to insulin glargine (glargine) as the basal insulin in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in terms of glycemic ...
Albright +22 more
core +1 more source
Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. [PDF]
PLoS ONE, 2011 BACKGROUND: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer initiation and promotion.
Chia-Hsuin Chang +6 more
doaj +1 more source